Skip to main content

Table 1 Distribution of tumor location and gender in patients with T2DM and cancer

From: Discovery and validation of PZP as a novel serum biomarker for screening lung adenocarcinoma in type 2 diabetes mellitus patients

Location Age Gender Total Proportion
Male Female
Lung 66.66 ± 8.36 448 66.08% 230 33.92% 678 20.84%
Colorectum 69.46 ± 10.01 250 59.95% 167 40.05% 417 12.81%
Stomach 68.75 ± 8.83 288 71.82% 113 28.18% 401 12.32%
Liver 67.80 ± 11.26 152 75.62% 49 24.38% 201 6.18%
Prostate 73.79 ± 7.97 193 100.00% 0 0.00% 193 5.93%
Breast 65.97 ± 11.45 4 2.27% 172 97.73% 176 5.41%
Blood 64.80 ± 11.30 97 58.08% 70 41.92% 167 5.13%
Pancreas 68.91 ± 9.24 97 63.82% 55 36.18% 152 4.67%
Bladder 70.02 ± 9.13 103 84.43% 19 15.57% 122 3.75%
Kidney 65.72 ± 10.50 73 66.97% 36 33.03% 109 3.35%
Esophagus 69.38 ± 8.44 67 67.00% 33 33.00% 100 3.07%
Lymphoma 67.11 ± 9.64 53 56.38% 41 43.62% 94 2.89%
Thyroid 53.52 ± 10.75 35 43.21% 46 56.79% 81 2.49%
Gallbladder & biliary 70.13 ± 10.07 40 53.33% 35 46.67% 75 2.30%
Uterus 63.57 ± 12.02 0 0.00% 74 100.00% 74 2.27%
Multiple sites 71.39 ± 10.33 32 69.57% 14 30.43% 46 1.41%
Head and neck 67.00 ± 10.45 24 77.42% 7 22.58% 31 0.95%
Ovary 63.48 ± 8.22 0 0.00% 25 100.00% 25 0.77%
Small intestine 70.86 ± 8.48 12 57.14% 9 42.86% 21 0.65%
Skin 70.88 ± 10.52 10 62.50% 6 37.50% 16 0.49%
Brain 65.13 ± 10.87 8 53.33% 7 46.67% 15 0.46%
Ureter 74.82 ± 6.66 7 63.64% 4 36.36% 11 0.34%
Thymus 58.30 ± 9.09 4 40.00% 6 60.00% 10 0.31%
Other 66.64 ± 10.15 24 61.54% 15 38.46% 39 1.20%
Total 67.70 ± 10.13 2021 62.11% 1233 37.89% 3254 100.00%
\